Freestone Grove Partners LP Purchases New Position in IQVIA Holdings Inc. $IQV

Freestone Grove Partners LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,320 shares of the medical research company’s stock, valued at approximately $38,706,000. Freestone Grove Partners LP owned approximately 0.12% of IQVIA at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at about $27,000. Compass Financial Management LLC acquired a new position in IQVIA during the second quarter worth approximately $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA in the fourth quarter valued at approximately $27,000. CrossGen Wealth LLC purchased a new position in shares of IQVIA during the fourth quarter worth approximately $28,000. Finally, Activest Wealth Management grew its position in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.8%

IQVIA stock opened at $261.57 on Thursday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $262.51. The firm has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. The stock’s fifty day moving average is $218.41 and its two-hundred day moving average is $188.59. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 EPS. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Robert W. Baird raised their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. upped their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Mizuho raised their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.